philips healthcare - innovations addressing unmet needs in ... · an integrated solution for...
TRANSCRIPT
Hans Hofstraat
Philips Research
May 21, 2010
Innovations Addressing Unmet Needs in Healthcare
Engaging All Stakeholders through Open Innovation
22
Healthcare‟s current reality
The consequencesThe issues
We are getting older and sicker
We expect better choices We have higher expectations about care and will
demand more choices in healthcare.
Demand for care is growing There are simply not enough nurses and doctors to
cope with our growing (and aging) population.
We don’t take good care of ourselves Obesity, heart disease and cancer are global health
issues that are worsened by the way we live.
By 2050, 50% of the developed world is projected to
be chronically ill.
Rate of change is accelerating Innovation introduces both complexity and promise
Male Female
>65
China Demographics 2050
3
The Philips Healthcare differenceCare cycle approach
3
People focused
We start with the needs of patients and
their care providers because understanding
their experiences ensures we create
solutions that best meet their needs.
CardiologyWomen’s
Health
Oncology
And we apply our technology to help improve healthcare
quality and reduce cost because meaningful innovations
create value for patients and care providers.
Meaningful innovation
CardiologyWomen’s
Health
Oncology
Care cycle driven
We focus on their
specific medical
needs throughout
the care cycle …
CardiologyWomen’s
Health
Oncology
…wherever that care occurs.
Care anywhere
44
Translational Healthcare researchDiagnostics and therapy development from bench to bedside
Research New optionsPatient Care
Partnerships between leading academic, medical institutions and industrial partners
are a key factor for effective translation of healthcare innovations into clinical practice
5
• Technology is key to address healthcare‟s needs,
but implementation of appropriate solutions in the
clinic and in the home also requires• Patient and user insights
• Biomedical know-how
• Clinical and application expertise
• New workflows
• New channels to market & business models
• Translation of opportunities into practice needs
collaboration between• Academic partners
• Clinical/care partners
• Patients
• Large and small companies with complementary expertise
• Governments, reimbursement agencies (e.g. insurers)
PPP‟s Drive Interaction Across Boundaries
To be able to provide meaningful and effective healthcare
solutions engagement of all stakeholders is needed
Public-Private Partnerships in HealthcareEngaging all Stakeholders
Patient
Provider of care
PayerProducer
6
An Example from Oncology Unmet need in chemotherapy
• Even if two cancer tumors are of the
same type and sub-type, they often
require significantly different therapy
regimes for optimal treatment
• Patients that respond to one type of
treatment frequently do not respond to
another
• Current therapeutic interventions
struggle to balance ratio of therapeutic
effects and toxicity (“therapeutic
index”) resulting in sub-optimal
treatments
• Technology helps to address these
unmet needs
Thermo-sensitive Drug Delivery SystemsUltrasound Mediated Delivery: Non-invasive, image-guided, precise
DTDT
Temperature induced drug delivery
Heat sensitive ‘vehicles’
HIFU – MRI delivery tool
Liposomes
• Approx. 200 nm
• Phospholipid shell
• Long circulation time (hours)
• High drug load inside particle
• Suitable for MR imaging
• MRI for imaging and control
• HIFU for heating to trigger
drug release
• Temperature sensitive vehicles
8
SonoDrugs projectImage-guided ultrasound induced drug delivery
4 years project (start 2008)
Industry partners:Philips (The Netherlands, Germany and Finland),
SME‟s Nanobiotix (France) and Lipoid (Germany).
University medical centers: Erasmus Medical Center (The Netherlands) and
University Clinic Münster (Germany).
Academic institutions: University of Cyprus (Cyprus), University of Gent
(Belgium), University of Helsinki (Finland), University of
London (United Kingdom), University of Tours (France),
University Victor Segalen Bordeaux (France), Eindhoven
University of Technology (The Netherlands), and the
University of Udine (Italy).
HIFU
Tabletop
MRI
• Small Molecules
– Increase therapeutic window
– Improve DMPK profile
• Biologics
– Improve access to target
– May allow lower doses
(lower cost)
• Nucleic acid-based
– Improve DMPK profile
– Improve egress from vascular
system to cytoplasm
Brandaris movie courtesy Annemieke van Wamel, Michel Versluis, and Nico de Jong, Erasmus MC Rotterdam- UTwente, NL
HIFU-MRI: Image-guided drug deliveryAddressing drug delivery challenges, enabling minimally
invasive, „targeted‟ treatment
4 cm
10
HIFU-MRI Mediated Drug Delivery An integrated solution for minimally-invasive, personalized therapy
2. Inject drug loaded carrier
A minimally-invasive technique to
increase locally the body’s uptake
of a pharmaceuticals by:
• temporarily increasing the local
permeability of tissue
• local drug release using ultrasound
activated drug delivery systems
3. Administer HIFU
5. Temperature Monitoring
and therapy feedback
4. Permeability of tissue increases, drug released
Microbubbles Liposomes
Acoustically active drug delivery carriers
1. Therapy Planning
HIFU-MRIHIFU-MRI
1111
Example of Pharma – MedTech partnershipHIFU-MRI for Drug Delivery
CELSION Thermodox® Concept:
“Target localized cancers with high
concentrations of chemo-therapeutics
through the use of our heat activated lipid
technology…”
Partnered with PHILIPS to Improve
Treatment
Non-Invasive, MRI-Guided, High Intensity
Focused Ultrasound (HIFU) approach
results in precisely defined tissue heating,
sharp thermal boundaries and real-time,
3-D thermometry, therapy planning
Oct 16, 2008
HIFU
Tabletop
MRI
Image source: Celsion investor presentation & Duke Univ.
Philips and Celsion Advance Development of Thermodox and
MR-guided HIFU…. Entering Preclinical Development
Sept 29, 2009
12
Open InnovationEngaging all stakeholders to bring meaningful innovations to healthcare
• Open Innovation means
– Bundling and sharing of R&D
– Public-private collaboration
– Investment in start-up companies
– Technology / IP acquisition and licensing
• IP is of key importance
– To protect and leverage intellectual assets
– To enable new business models
– To facilitate collaborations
– To support product development and market-launch
Patient
Provider of care
PayerProducer
Successful Approaches to Open Innovation• Guidelines for successful Open Innovation*
– Culture and approach
• Treat collaboration strategically
• Foster strong institutions
• Organize for lasting relationships
• Align interests
• Establish clear intent
• View innovation as a trans-disciplinary activity
– Organization
• Provide the right professional skills
• Provide relevant training
• Use standard practices and communicate regularly
– Outcomes
• Achieve effective Intellectual Property
• Implementation tools, including
– Checklists for self-assessment
– Clarifications on avoiding indirect state aid13
* Based on „Responsible Partnering‟
• Innovations that address unmet patient‟s needs
• Clinical validation, healthcare economics aspects, …
• Effective implementation routes, engaging all stakeholders
• New business models, alliances,….
… and for Healthcare
• Initiated in 2004 by EIRMA,
EUA, EARTO, ProTon Europe
• Handbook updated in 2009
See http://www.responsible-partnering.org/
14
• High Tech Campus Eindhoven has become the embodiment of the Open
Innovation philosophy
• It is an 'ecosystem' of high-tech R&D companies (Corporate, SME‟s, start-up‟s),
academic and research institutes, and support services operating in related fields
• New initiative LifeTec4Health
• Enabling innovation at the interface between life sciences and medical technology
• Building on a public-private partnership started by TU Eindhoven and Philips
• Accelerating the transfer from ideas to new business
From Co-ordination to Co-creationOpen innovation in a Co-located Ecosystem
Facts & Figures:Campus site covers 103 hectares
Over 90 companies
5 institutes
Over 7,000 R&D engineers
50 nationalities
45,000 m2 laboratory space
185,000 m2 operational office space
6,000 m2 space for start-up
companies
More than € 500M invested by Philips
The best environment:Infrastructure
Quality & Regulatory
Entrepreneurs
Ramp-up with (flexible) talent
Dedicated training and education
Legal support
IP support
Access to venture capital
15
• High Tech Campus Eindhoven has become the embodiment of the Open
Innovation philosophy
• It is an 'ecosystem' of high-tech R&D companies (Corporate, SME‟s, start-up‟s),
academic and research institutes, and support services operating in related fields
• New initiative LifeTec4Health
• Enabling innovation at the interface between life sciences and medical technology
• Building on a public-private partnership started by TU Eindhoven and Philips
• Accelerating the transfer from ideas to new business
From Co-ordination to Co-creationOpen innovation in a Co-located Ecosystem
Facts & Figures:Campus site covers 103 hectares
Over 90 companies
5 institutes
Over 7,000 R&D engineers
50 nationalities
45,000 m2 laboratory space
185,000 m2 operational office space
6,000 m2 space for start-up
companies
More than € 500M invested by Philips
The best environment:Infrastructure
Quality & Regulatory
Entrepreneurs
Ramp-up with (flexible) talent
Dedicated training and education
Legal support
IP support
Access to venture capital
Start Up’s
and SME’s
benefit from
presence of
Corporates,
Research
Institutes and
Supporting
Services &
Infrastructure
Research
Institutes
Start Up’s
SME’s
Consultancy
& Services
Corporate
Innovators
EIB fostering Open InnovationRisk Sharing Finance Facility
16
EIB Risk Sharing Finance Facility is an innovative scheme to improve access
to financing of research, development and innovation (RDI)
• Key factor to improve European competitiveness and ensure long term economic
growth and employment
• Supporting RDI projects which have a difficulty in getting private funding, such as:
– Complex products and technologies • Products with a high risk, e.g. due to long time to reward (Healthcare products!)
– Unproven markets• Market and business model innovation are required for innovative healthcare solutions
European Investment Bank and Philips sign EUR 200 million healthcare R&D loan agreement
Release date: 02 December 2009 Reference: 2009-240-EN
The European Investment Bank (EIB) and Royal Philips Electronics (AEX: PHI, NYSE: PHG) have signed a EUR 200
million loan agreement. The 10 year loan, provided under the Risk-Sharing Finance Facility (RSFF) will be used to
finance research and development (R&D) activities across a range of innovative healthcare projects, including image-
guided intervention and home healthcare, in Europe.
Philips will use the EUR 200 million loan from the EIB as part of its planned research and development investment in healthcare
activities in Corporate Technologies. These R&D activities will be focused on healthcare solutions such as image-guided
intervention and therapy, home healthcare, and clinical decision support systems. The R&D will take place in an open
innovation environment, collaborating with Small and Medium Enterprises (SME), research institutes and universities
across Europe. Philips is the first company to receive EIB funding as a result of its efforts to fuel open innovation.
Summary and conclusions
17
• Healthcare poses a major societal challenge - and a
significant business opportunity (# 1 Global service market)
• Solutions based on novel technologies („convergent
technologies‟) can address these challenges
• Successful innovation in healthcare requires engagement
of all stakeholders: Public Private Partnership
• Open Innovation is a key success factor for the effective
translation of new healthcare concepts into clinical practice
• Open Innovation flourishes when the partners:– Act as responsible partners
– Share the same goals
– Are motivated and aligned
– Trust each other
– Share information across disciplines
– Build on mutual strengths
• From Co-Ordination to Co-Location and Co-Creation
– Campuses and Clusters of Innovation
Patient
Provider of care
PayerProducer
1818